RE:RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer August 12, 2024 - Oncology, rare diseases, and immunology will likely continue to be hot targets for investors, and snapping up drugs from smaller startups has advantages over in-house development.
“What we’re seeing is the elimination of riskier and longer-shot products in the R&D portfolio for the big pharma companies, basically swapping those out for acquisitions with more potential than the products they’re cutting,” according to Michael Abrams , Managing Partner, Numerof & Associates.
August 16, 2024 - The departure of a star scientist (Ira Mellman) and the recent changes at Genentech—which prides itself as the world’s very first biotech—once again raised the question of whether it’s necessary for Big Pharma companies to keep large academia-like early translational research organizations such as gRED when buying out assets from small biotechs seems more cost-efficient.
https://www.fiercebiotech.com/biotech/genentech-shut-down-cancer-immunology-department-amid-broader-downsizing-efforts